Free RAC Product Labeling and Advertising Questions and Answers 1 — Questions and Answers
Question 1: A pharmaceutical company plans to launch a direct-to-consumer (DTC) television advertisement for a prescription drug. According to FDA regulations (21 CFR 202.1), what is a mandatory component of this type of advertisement?
- A statement that the product is available by prescription only.
- The complete prescribing information scrolled on the screen.
- A "major statement" presented in a clear, conspicuous, and neutral manner, disclosing the major side effects and contraindications. (Correct answer)
- Pre-approval of the advertisement's final script by the Office of Prescription Drug Promotion (OPDP).
Correct answer: A "major statement" presented in a clear, conspicuous, and neutral manner, disclosing the major side effects and contraindications.
FDA regulations require that broadcast advertisements for prescription drugs include a "major statement" of the most important risks. This must be conveyed in a clear, conspicuous, and neutral manner. While the ad must make "adequate provision" for viewers to obtain the full prescribing information (e.g., via a website or phone number), the full text is not required in the ad itself. Pre-approval by OPDP is generally not required.
Question 2: In the United States, regulatory authority over the advertising of drug and device products is divided between the FDA and another agency. The advertising for over-the-counter (OTC) drugs is primarily regulated by which of the following?
- The Federal Trade Commission (FTC) (Correct answer)
- The Drug Enforcement Administration (DEA)
- The Consumer Product Safety Commission (CPSC)
- The Office of the National Coordinator for Health Information Technology (ONC)
Correct answer: The Federal Trade Commission (FTC)
Through a long-standing agreement, the Federal Trade Commission (FTC) has primary jurisdiction over the advertising of over-the-counter (OTC) drugs, foods, and cosmetics to ensure claims are truthful and not deceptive. The FDA retains authority over the labeling of these products and the advertising of prescription drugs.
Question 3: Which of the following activities is MOST likely to be considered prohibited "off-label promotion" by a pharmaceutical company representative?
- A Medical Science Liaison (MSL) providing a physician with a copy of a peer-reviewed journal article describing an unapproved use, in response to the physician's unsolicited request.
- A sales representative proactively detailing physicians on using their approved analgesic for a new type of pain not included in the Prescribing Information. (Correct answer)
- Sponsoring an independent Continuing Medical Education (CME) event where an unapproved use is discussed by the academic speaker.
- Including data from a trial on an unapproved indication in an investor relations presentation.
Correct answer: A sales representative proactively detailing physicians on using their approved analgesic for a new type of pain not included in the Prescribing Information.
A sales representative's role is strictly promotional and limited to the on-label, approved indications for a drug. Proactively discussing or encouraging an unapproved (off-label) use is a clear violation of FDA regulations. In contrast, Medical Science Liaisons (MSLs) can reactively provide truthful, non-misleading scientific information, such as published articles, in response to unsolicited requests from healthcare providers.
Question 4: A medical device manufacturer is preparing labeling for a Class IIa sterile device to be marketed in the European Union. According to the Medical Device Regulation (EU 2017/745), which of the following must be affixed to the device label?
- The CE mark followed by the four-digit identification number of the Notified Body. (Correct answer)
- The full address of the European Competent Authority that reviewed the technical documentation.
- The UL (Underwriters Laboratories) certification symbol.
- The CE mark alone, without any additional numbers.
Correct answer: The CE mark followed by the four-digit identification number of the Notified Body.
Under the EU MDR, devices that require the involvement of a Notified Body for conformity assessment (including Class IIa, IIb, and III devices) must bear the CE mark followed by the Notified Body's unique four-digit identification number. This signifies that the Notified Body has reviewed and certified the manufacturer's conformity assessment. Class I devices that are not sterile or have no measuring function are self-certified and bear the CE mark alone.
Question 5: A pharmaceutical company becomes aware of new data confirming a causal link between its marketed drug and a previously unknown serious adverse reaction. To update the Prescribing Information to add a new warning, which is the MOST appropriate regulatory submission to the FDA?
- An annual report.
- A "Changes Being Effected" (CBE-0) supplement. (Correct answer)
- A New Drug Application (NDA).
- A Prior Approval Supplement (PAS).
Correct answer: A "Changes Being Effected" (CBE-0) supplement.
For critical safety-related labeling changes, such as adding or strengthening a contraindication, warning, precaution, or adverse reaction, regulations permit the submission of a "Changes Being Effected" (CBE-0) supplement. This allows the applicant to implement the change immediately upon the FDA's receipt of the supplement, ensuring rapid communication of important safety information. A PAS would require FDA approval before implementation, causing a delay.
Question 6: According to U.S. FDA regulations for medical device labeling (21 CFR 801), which of the following is a required element on the label of a device intended for prescription use?
- The Unique Device Identifier (UDI) in plain-text format only.
- The statement "Caution: Federal law restricts this device to sale by or on the order of a physician" or the symbol "Rx Only". (Correct answer)
- The reimbursement code for the device.
- The date of the last FDA inspection of the manufacturing facility.
Correct answer: The statement "Caution: Federal law restricts this device to sale by or on the order of a physician" or the symbol "Rx Only".
21 CFR 801.109 specifies that a device restricted to use by or on the order of a licensed practitioner must bear either the full cautionary statement or the symbol "Rx Only" on its label. While the UDI is required on most device labels, it must be in both a human-readable (plain-text) and a machine-readable format. Reimbursement codes and inspection dates are not required label elements.
Free RAC Product Labeling and Advertising Questions and Answers 1
A pharmaceutical company plans to launch a direct-to-consumer (DTC) television advertisement for a prescription drug.
According to FDA regulations (21 CFR 202.1), what is a mandatory component of this type of advertisement?